Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
SORAFENIB INDUCED ACNEIFORM ERUPTIONS: A CASE REPORT
View through CrossRef
ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Sorafenib acts by inhibiting various kinases like tyrosine kinase, RET tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis and cell proliferation. Acneiform eruptions are known side effect of EGFR inhibitors with incidence ranging between 20 to 90 percent [3], but acneiform eruptions with Sorafenib is seldom seen. Hence, we report a case of Sorafenib induced acneiform eruptions.Keywords: Sorafenib, EGFR, acneiform eruptions, adverse drug reactions
Innovare Academic Sciences Pvt Ltd
Title: SORAFENIB INDUCED ACNEIFORM ERUPTIONS: A CASE REPORT
Description:
ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer.
Sorafenib acts by inhibiting various kinases like tyrosine kinase, RET tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis and cell proliferation.
Acneiform eruptions are known side effect of EGFR inhibitors with incidence ranging between 20 to 90 percent [3], but acneiform eruptions with Sorafenib is seldom seen.
Hence, we report a case of Sorafenib induced acneiform eruptions.
Keywords: Sorafenib, EGFR, acneiform eruptions, adverse drug reactions.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma
Abstract
Background:
Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the second leading cause of cancer-related death wo...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
Study objective: Sorafenib an antiangiogenic drug which are widely used in cancer treatment, and it inhibits vascular endothelial growth factor (VEGF) and tyrosine kinases (TK)invo...
Abstract 4266: Acquired resistance to sorafenib yields CXCL12 (SDF1α) over-expression and increases invasion in hepatocarcinoma cells
Abstract 4266: Acquired resistance to sorafenib yields CXCL12 (SDF1α) over-expression and increases invasion in hepatocarcinoma cells
Abstract
Background: Sorafenib has a well known efficacy in patients with advanced hepatocellular carcinoma (HCC). Sorafenib displays antiangiogenic effects by targe...
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.
Abstract
Abstract 2060
Poster Board II-37
Introduction:
The Flt3-internal tandem duplication can b...
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Abstract
Background
Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), but its use is hampered by the secondary drug resistance. Y...
Abstract 4145: Increased anti-tumor effect of sorafenib by depleting tumor associated macrophages
Abstract 4145: Increased anti-tumor effect of sorafenib by depleting tumor associated macrophages
Abstract
Background: Sorafenib prolonged survival in patients with unresectable hepatocellular carcinoma (HCC), but the effect is modest and tumor finally progressed...